| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Deschatelets Pascal | Chief Scientific Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM | /s/ David Watson, attorney-in-fact for Pascal Deschatelets | 15 Jan 2026 | 0001657720 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLS | Common Stock | Sale | $50,520 | -2,277 | -0.2% | $22.19 | 1,158,219 | 13 Jan 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 12, 2026. |